PF-00547659 | ||||
Placebo | 22.5 mg | 75 mg | 225 mg | |
CDAI-100 response | ||||
Week 8 | ||||
N | 56 | 50 | 55 | 62 |
Patients, % | 41.4 | 50.5 | 48.3 | 57.0 |
90% CI | –11.3 to 29.5 | –13.0 to 26.8 | –3.6 to 34.8 | |
Week 12 | ||||
N | 54 | 51 | 49 | 61 |
Patients, % | 44.4 | 56.0 | 47.7 | 53.8 |
90% CI | –8.7 to 31.9 | –17.3 to 24.0 | –10.1 to 29.1 | |
CDAI remission | ||||
Week 8 | ||||
N | 57 | 50 | 56 | 62 |
Patients, % | 16.7 | 29.1 | 23.8 | 26.9 |
90% CI | –5.2 to 29.9 | –9.2 to 23.4 | –6.2 to 26.6 | |
Week 12 | ||||
N | 55 | 51 | 49 | 61 |
Patients, % | 23.0 | 26.8 | 28.5 | 29.6 |
90% CI | –14.6 to 22.2 | –13.6 to 24.6 | –11.6 to 24.8 |
CDAI, Crohn’s Disease Activity Index.